Details

---

• Active Ingredient: Each tablet contains 0.5 mg of cabergoline.

• Manufacturer: Pfizer Italia S.r.l., Italy.

• Registration in Malaysia: Registered with the National Pharmaceutical Regulatory Agency (NPRA) under registration number MAL19971775AZ

Indications

• Inhibition of Physiological Lactation: To prevent the onset of lactation soon after childbirth.

• Suppression of Established Lactation: To suppress lactation in cases where breastfeeding is not desired.

• Treatment of Hyperprolactinaemic Disorders: Including conditions such as prolactinomas, amenorrhoea, and infertility due to elevated prolactin levels.
  
   

Instructions for Use

• Administration: Take orally with food to enhance tolerability.

• Dosage:

  • Inhibition of Physiological Lactation: 1 mg (two 0.5 mg tablets) as a single dose on the first day postpartum.

  • Suppression of Established Lactation: 0.25 mg (half a 0.5 mg tablet) every 12 hours for two days.

  • Hyperprolactinaemic Disorders: Starting dose of 0.5 mg per week, administered in one or two doses. The dose may be gradually increased by 0.5 mg per week at monthly intervals, up to a maximum of 4.5 mg per week.

• Missed Dose: If a dose is missed, take it as soon as remembered unless it's almost time for the next dose. Do not double the dose to make up for a missed one.

• Overdose: Symptoms may include nausea, vomiting, dizziness, and hypotension. Seek immediate medical attention if overdose is suspected.